Advanced glycation end product Nε-carboxymethyllysine induces endothelial cell injury: The involvement of SHP-1-regulated VEGFR-2 dephosphorylation

Journal of Pathology

Volumn 230, Issue 2, 2013, Pages 215-227

  Liu, Shing Hwa ^a   Sheu, Wayne Huey Herng ^b,c   Lee, Maw Rong ^c   Lee, Wen Jane ^b   Yi, Yu Chiao ^b   Yang, Tzung Jie ^c   Jen, Jen Fon ^c   Pan, Hung Chuan ^b,c   Shen, Chin Chang ^d,e   Chen, Wen Bao ^c   Tien, Hsing Ru ^c   Sheu, Meei Ling ^b,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

Author keywords

AGEs; CML; human endothelial cells; NADPH oxidase; ROS; SHP 1

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; PROTEIN TYROSINE PHOSPHATASE SHP 1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMALL INTERFERING RNA; VASCULOTROPIN RECEPTOR 2;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME ANALYSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANIMALS; AORTA; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; GENE SILENCING; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LYSINE; MALE; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84877729596     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4045     Document Type: Article

References (41)

1. ε- (Carboxymethyl)lysine depositions in intramyocardial blood vessels in human and rat acute myocardial infarction: a predictor or reflection of infarction? Arterioscler Thromb Vasc Biol 2006; 26: 2497-2503.
2. Johnstone MT, Creager SJ, Scales KM, et al., Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88: 2510-2516.
3. Wihler C, Schafer S, Schmid K, et al., Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition. Diabetologia 2005; 48: 1645-1653.
4. Penfold SA, Coughlan MT, Patel SK, et al., Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int 2010; 78: 287-295.
5. Tam HL, Shiu SW, Wong Y, et al., Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis 2010; 209: 173-177.
6. Guo ZJ, Niu HX, Hou FF, et al., Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal 2008; 10: 1699-1712.
7. Xu B, Chibber R, Ruggiero D, et al., Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 2003; 17: 1289-1291.
8. Goldin A, Beckman JA, Schmidt AM, et al., Advanced glycation end products sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605.
9. Veves A, King GL,. Can VEGF reverse diabetic neuropathy in human subjects? J Clin Invest 2001; 107: 1215-1218.
10. Isner JM,. Tissue responses to ischemia: local and remote responses for preserving perfusion of ischemic muscle. J Clin Invest 2000; 106: 615-619.
11. Kalka C, Masuda H, Takahashi T, et al., Vascular endothelial growth factor (165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000; 86: 1198-1202.
12. Schwarz ER, Speakman MT, Patterson M, et al., Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat-angiogenesis and angioma formation. J Am Coll Cardiol 2000; 35: 1323-1330.
13. Conway EM, Collen D, Carmeliet P,. Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001; 49: 507-521.
14. Park CW, Kim HW, Lim JH, et al., Vascular endothelial growth factor inhibition by dRK6 causes endothelial apoptosis, fibrosis, and inflammation in the heart via the Akt/eNOS axis in db/db mice. Diabetes 2009; 58: 2666-2676.
15. Bhattacharya R, Kwon J, Wang E, et al., Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF receptor-2 and attenuates endothelial DNA synthesis, but not migration. J Mol Signal 2008; 3: 8.
16. Huang L, Sankar S, Lin C, et al., HCPTPA, a protein tyrosine phosphatase that regulates vascular endothelial growth factor receptor-mediated signal transduction and biological activity. J Biol Chem 1999; 274: 38183-38188.
17. Su X, Zhou T, Yang PA, et al., Hematopoietic cell protein-tyrosine phosphatase-deficient motheaten mice exhibit T cell apoptosis defect. J Immunol 1996; 156: 4198-4208.
18. Thangaraju M, Sharma K, Liu D, et al., Interdependent regulation of intracellular acidification and SHP-1 in apoptosis. Cancer Res 1999; 59: 1649-1654.
19. Sugano M, Tsuchida K, Hata T, et al., RNA interference targeting SHP-1 attenuates myocardial infarction in rats. FASEB J 2005; 19: 2054-2056.
20. Ushio-Fukai M,. Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovasc Res 2006; 71: 226-235.
21. Park HJ, Zhang Y, Georgescu SP, et al., Human umbilical vein endothelial cells and human dermal microvascular endothelial cells offer new insights into the relationship between lipid metabolism and angiogenesis. Stem Cell Rev 2006; 2: 93-102.
22. Sheu ML, Chiang CK, Tsai KS, et al., Inhibition of NADPH oxidase-related oxidative stress-triggered signaling by honokiol suppresses high glucose-induced human endothelial cell apoptosis. Free Radic Biol Med 2008; 44: 2043-2050.
23. Sheu ML, Ho FM, Yang RS, et al., High glucose induces human endothelial cell apoptosis through a phosphoinositide 3-kinase-regulated cyclooxygenase-2 pathway. Arterioscler Thromb Vasc Biol 2005; 25: 539-545.
24. Sheu ML, Ho FM, Chao KF, et al., Activation of phosphoinositide 3-kinase in response to high glucose leads to regulation of reactive oxygen species-related nuclear factor-kappaB activation and cyclooxygenase-2 expression in mesangial cells. Mol Pharmacol 2004; 66: 187-196.
25. Sheu ML, Liu SH, Lan KH,. Honokiol induces calpain-mediated glucose-regulated protein-94 cleavage and apoptosis in human gastric cancer cells and reduces tumor growth. PLoS One 2007; 2: e1096.
26. Kunsch C, Medford RM,. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999; 85: 753-766.
27. Shimotake J, Derugin N, Wendland M, et al., Vascular endothelial growth factor receptor-2 inhibition promotes cell death and limits endothelial cell proliferation in a neonatal rodent model of stroke. Stroke 2010; 41: 343-349.
28. Nakagami H, Cui TX, Iwai M, et al., Tumor necrosis factor-alpha inhibits growth factor-mediated cell proliferation through SHP-1 activation in endothelial cells. Arterioscler Thromb Vasc Biol 2002; 22: 238-242.
29. Baynes JW,. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-412.
30. Rupin A, Paysant J, Sansilvestri-Morel P, et al., Role of NADPH oxidase-mediated superoxide production in the regulation of E-selectin expression by endothelial cells subjected to anoxia/reoxygenation. Cardiovasc Res 2004; 63: 323-330.
31. Mustapha NM, Tarr JM, Kohner EM, et al., NADPH oxidase versus mitochondria-derived ROS in glucose-induced apoptosis of pericytes in early diabetic retinopathy. J Ophthalmol 2010; 2010: 746978.
32. Soro-Paavonen A, Watson AM, Li J, et al., Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008; 57: 2461-2469.
33. Cai W, Gao QD, Zhu L, et al., Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 2002; 8: 337-346.
34. Hui YY, McAmis WC, Baynes JW, et al., Effect of advanced glycation end products on oxidative stress in endothelial cells in culture: a warning on the use of cells studied in serum-free media. Diabetologia 2001; 44: 1310-1317.
35. Barrett DM, Black SM, Todor H, et al., Inhibition of protein-tyrosine phosphatases by mild oxidative stresses is dependent on S-nitrosylation. J Biol Chem 2005; 280: 14453-14461.
36. Lee SR, Kwon KS, Kim SR, et al., Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J Biol Chem 1998; 273: 15366-15372.
37. Sullivan DM, Wehr NB, Fergusson MM, et al., Identification of oxidant-sensitive proteins: TNF-alpha induces protein glutathiolation. Biochemistry 2000; 39: 11121-11128.
38. Weibrecht I, Bohmer SA, Dagnell M, et al., Oxidation sensitivity of the catalytic cysteine of the protein-tyrosine phosphatases SHP-1 and SHP-2. Free Radic Biol Med 2007; 43: 100-110.
39. Groen A, Lemeer S, van der Wijk T, et al., Differential oxidation of protein-tyrosine phosphatases. J Biol Chem 2005; 280: 10298-10304.
40. Yeh CH, Sturgis L, Haidacher J, et al., Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 2001; 50: 1495-1504.
41. Basta G, Sironi AM, Lazzerini G, et al., Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006; 91: 4628-4634.